<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04626635</url>
  </required_header>
  <id_info>
    <org_study_id>R7075-ONC-2009</org_study_id>
    <nct_id>NCT04626635</nct_id>
  </id_info>
  <brief_title>REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors</brief_title>
  <acronym>COMBINE-EGFR-1</acronym>
  <official_title>A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is:&#xD;
&#xD;
      Dose Escalation:&#xD;
&#xD;
      • To assess the safety and tolerability of a REGN7075 monotherapy lead-in and REGN7075 in&#xD;
      combination with cemiplimab in patients with advanced solid tumors&#xD;
&#xD;
      Dose Expansion:&#xD;
&#xD;
      • To assess the preliminary efficacy of REGN7075 in combination with cemiplimab within&#xD;
      selected advanced solid tumor-specific cohorts, as measured by objective response rate (ORR)&#xD;
      per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and/or composite&#xD;
      response criteria&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
      Dose Escalation:&#xD;
&#xD;
        -  To characterize the pharmacokinetics (PK) of REGN7075 alone and in combination with&#xD;
           cemiplimab&#xD;
&#xD;
        -  To assess the preliminary efficacy of REGN7075 in combination with cemiplimab, as&#xD;
           measured by ORR, overall survival (OS), progression free survival (PFS), duration of&#xD;
           response (DOR), complete response (CR) rate, and disease control rate (DCR) per RECIST&#xD;
           1.1 and/or composite response criteria&#xD;
&#xD;
        -  To assess immunogenicity of REGN7075 and cemiplimab&#xD;
&#xD;
      Dose Expansion:&#xD;
&#xD;
        -  To assess the preliminary efficacy of REGN7075 in combination with cemiplimab within&#xD;
           selected advanced solid tumor-specific cohorts of patients as measured by OS, PFS, DOR,&#xD;
           CR rate, and DCR per RECIST 1.1 and/or composite response criteria&#xD;
&#xD;
        -  To assess the safety and tolerability of REGN7075 in combination with cemiplimab&#xD;
&#xD;
        -  To characterize the PK of REGN7075 alone and in combination with cemiplimab&#xD;
&#xD;
        -  To assess immunogenicity to REGN7075 and cemiplimab&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">April 3, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of dose-limiting toxicities (DLTs) during the DLT period</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Approximately 90 days from last dose; up to 5 years</time_frame>
    <description>Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events of special interest (AESIs)</measure>
    <time_frame>Approximately 90 days from last dose; up to 5 years</time_frame>
    <description>Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of serious adverse events (SAEs)</measure>
    <time_frame>Approximately 90 days from last dose; up to 5 years</time_frame>
    <description>Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of grade ≥3 laboratory abnormalities</measure>
    <time_frame>Approximately 90 days from last dose; up to 5 years</time_frame>
    <description>Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose expansion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug concentrations of REGN7075 in serum</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation and dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug concentrations of cemiplimab</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation and dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation and dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation and dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation and dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation and dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Dose escalation and dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADA) to REGN7075</measure>
    <time_frame>Approximately 90 days from last dose; up to 5 years</time_frame>
    <description>Dose escalation and dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ADA to cemiplimab</measure>
    <time_frame>Approximately 90 days from last dose; up to 5 years</time_frame>
    <description>Dose escalation and dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of TEAEs</measure>
    <time_frame>Approximately 90 days from last dose; up to 5 years</time_frame>
    <description>Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of AESIs</measure>
    <time_frame>Approximately 90 days from last dose; up to 5 years</time_frame>
    <description>Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of SAEs</measure>
    <time_frame>Approximately 90 days from last dose; up to 5 years</time_frame>
    <description>Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of grade ≥3 laboratory abnormalities</measure>
    <time_frame>Approximately 90 days from last dose; up to 5 years</time_frame>
    <description>Dose expansion</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Variety of mixed advanced solid tumor types</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microsatellite-Stable Colorectal Cancer (MSS CRC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triple Negative Breast Cancer (TNBC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cutaneous Squamous Cell Carcinoma (CSCC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-Small Cell Lung Cancer (NSCLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Head and Neck Squamous Cell Carcinoma (HNSCC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN7075</intervention_name>
    <description>Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion A</arm_group_label>
    <arm_group_label>Dose Expansion B</arm_group_label>
    <arm_group_label>Dose Expansion C</arm_group_label>
    <arm_group_label>Dose Expansion D</arm_group_label>
    <arm_group_label>Dose Expansion E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cemiplimab</intervention_name>
    <description>administered concomitantly Q3W by IV infusion or SC injection</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion A</arm_group_label>
    <arm_group_label>Dose Expansion B</arm_group_label>
    <arm_group_label>Dose Expansion C</arm_group_label>
    <arm_group_label>Dose Expansion D</arm_group_label>
    <arm_group_label>Dose Expansion E</arm_group_label>
    <other_name>REGN2810</other_name>
    <other_name>Libtayo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. ≥18 years of age (≥20 years of age for patients enrolled in Japan)&#xD;
&#xD;
          2. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          3. Has histologically or cytologically confirmed cancer that meets criteria as defined in&#xD;
             the protocol&#xD;
&#xD;
          4. Expansion Cohorts only: Is anti-programmed cell death protein-1 (PD-1)/programmed cell&#xD;
             death ligand-1 (PD-L1) naïve, defined as never having previously been treated with a&#xD;
             drug that targets the PD-1&#xD;
&#xD;
          5. Has at least 1 lesion that meets study criteria as defined in the protocol&#xD;
&#xD;
          6. Willing to provide tumor tissue from newly obtained biopsy (at a minimum core biopsy)&#xD;
             from a tumor site that has not been previously irradiated&#xD;
&#xD;
          7. Has adequate organ and bone marrow function as defined in the protocol&#xD;
&#xD;
          8. In the judgement of the investigator, has a life expectancy of at least 3 months&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Is currently participating in another study of a therapeutic agent&#xD;
&#xD;
          2. Has participated in any study of an investigational agent or an investigational device&#xD;
             within 4 weeks of the first administration of study drug as defined in the protocol&#xD;
&#xD;
          3. Has received treatment with an approved systemic therapy within 4 weeks of the first&#xD;
             administration of study drug or has not yet recovered (ie, grade 1 or baseline) from&#xD;
             any acute toxicities&#xD;
&#xD;
          4. Has received recent anti-epidermal growth factor receptor (EGFR) antibody therapy as&#xD;
             defined in the protocol&#xD;
&#xD;
          5. Has received radiation therapy or major surgery within 14 days of the first&#xD;
             administration of study drug or has not recovered (ie, grade 1 or baseline) from&#xD;
             adverse events&#xD;
&#xD;
          6. Has received any previous systemic, non-immunomodulatory biologic therapy within 4&#xD;
             weeks of first administration of study drug.&#xD;
&#xD;
          7. Has had prior anti-cancer immunotherapy within 5 half-lives prior to study drug as&#xD;
             defined in the protocol&#xD;
&#xD;
          8. Has second malignancy that is progressing or requires active treatment as defined in&#xD;
             the protocol&#xD;
&#xD;
          9. Has any condition requiring ongoing/continuous corticosteroid therapy (&gt;10 mg&#xD;
             prednisone/day or anti-inflammatory equivalent) within 1-2 weeks prior to the first&#xD;
             dose of study drug as defined in the protocol&#xD;
&#xD;
         10. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease or&#xD;
             any other condition that required treatment with systemic immunosuppressive treatments&#xD;
             as defined in the protocol&#xD;
&#xD;
         11. Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease,&#xD;
             or spinal cord compression&#xD;
&#xD;
         12. Has encephalitis, meningitis, organic brain disease (eg, Parkinson's disease) or&#xD;
             uncontrolled seizures within 1 year prior to the first dose of study drug&#xD;
&#xD;
         13. Has any ongoing inflammatory skin disease as defined in the protocol NOTE: Other&#xD;
             protocol-defined Inclusion/ Exclusion Criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Variety of mixed advanced solid tumor types</keyword>
  <keyword>First in Human (FIH)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

